Published in Cancer Weekly, October 16th, 1995
Data were presented on the first 23 of 51 patients enrolled in the multicenter trial as of September 15, 1995. These patients had received treatment for at least two months with Targretin Topical (LGD1069), a compound discovered by Ligand scientists which selectively activates a subclass of retinoid...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.